Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1980 Nov;42(5):703–711. doi: 10.1038/bjc.1980.305

The antitumour activity of maltose tetrapalmitate compared with other immunoadjuvants, and its effectiveness after tumour surgery.

H El Kappany, C Chopra, V N Nigam, C A Brailovsky, M Elhilali
PMCID: PMC2010533  PMID: 7459208

Abstract

The effectivenss of maltose tetrapalmitate (MTP) as an antitumour immune adjuvant was verified by its comparison with other known immunopotentiators, namely BCG, Corynebacterium parvum, levamisole and pyran copolymer. Copenhagen x Fisher 344/CRBL F1 hybrid male rats inoculated s.c. with the Dunning R3327A prostatic adenocarcinoma were used as the test system. All animals treated with immunoadjuvants showed a delay in tumour appearance and inhibition of early tumour growth. MTP was found to be the most effective, followed by levamisole, BCG, pyran copolymer and C. parvum in order of decreasing efficacy. Intratumoral treatment of small or large s.c. tumours with BCG, MTP and C. parvum was ineffective in our cases. However, this treatment was effective with MTP and BCG if they were used against a differentiated form of R3327 tumour. MTP and levamisole were found to be equally effective when given orally in drinking water. Experiments involving surgical excision of tumours followed by MTP therapy in two s.c. implanted animal tumour models (viz. a poorly immunogenic ascites mammary carcinoma 13762 in Fisher 344/CRBL rats, and an SV40 virus-induced sarcoma of low immunogenicity in Syrian hamster) showed beneficial effects of MTP on local tumour recurrence and tumour growth. Pre- and postoperative MTP treatment was at least as effective as postoperative MTP treatment alone.

Full text

PDF
703

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Berd D. A., Mitchell M. S. Immunological enhancement of leukemia L1210 by Corynebacterium parvum in allogeneic mice. Cancer Res. 1976 Nov;36(11 Pt 1):4119–4124. [PubMed] [Google Scholar]
  2. Bruley-Rosset M., Florentin I., Kiger N., Davigny M., Mathé G. Effects of Bacillus Calmette-Guérin and levamisole on immune responses in young adult and age-immunodepressed mice. Cancer Treat Rep. 1978 Nov;62(11):1641–1650. [PubMed] [Google Scholar]
  3. Came P. E., Moore D. H. Inhibition of spontaneous mammary carcinoma of mice by treatment with interferon and poly I:C. Proc Soc Exp Biol Med. 1971 May;137(1):304–305. doi: 10.3181/00379727-137-35565. [DOI] [PubMed] [Google Scholar]
  4. Carbone P. P. Tumor biology and clinical trials: the Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res. 1977 Dec;37(12):4239–4245. [PubMed] [Google Scholar]
  5. Chedid L., Audibert F., Johnson A. G. Biological activities of muramyl dipeptide, a synthetic glycopeptide analogous to bacterial immunoregulating agents. Prog Allergy. 1978;25:63–105. [PubMed] [Google Scholar]
  6. Chihara G., Hamuro J., Maeda Y., Arai Y., Fukuoka F. Antitumor polysaccharide derived chemically from natural glucan (pachyman). Nature. 1970 Mar 7;225(5236):943–944. doi: 10.1038/225943a0. [DOI] [PubMed] [Google Scholar]
  7. Faanes R. B., Dillon P., Choi Y. S. Levamisole augments the cytotoxic T-cell response depending on the dose of drugs and antigen administered. Clin Exp Immunol. 1977 Mar;27(3):502–506. [PMC free article] [PubMed] [Google Scholar]
  8. Fisher B., Gebhardt M., Linta J., Saffer E. Comparison of the inhibition of tumor growth following local or systemic administration of Corynebacterium parvum or other immunostimulating agents with or without cyclophosphamide. Cancer Res. 1978 Sep;38(9):2679–2687. [PubMed] [Google Scholar]
  9. Hawrylko E., Mackaness G. B. Immunopotentiation with BCG. 3. Modulation of the response to a tumor-specific antigen. J Natl Cancer Inst. 1973 Nov;51(5):1677–1682. doi: 10.1093/jnci/51.5.1677. [DOI] [PubMed] [Google Scholar]
  10. Hersh E. M., Gutterman J. U., Mavligit G. M. Immunotherapy of human cancer. Adv Intern Med. 1977;22:145–185. [PubMed] [Google Scholar]
  11. Mathé G., Kamel M., Dezfulian M., Halle-Pannenko O., Bourut C. An experimental screening for "systemic adjuvants of immunity" applicable in cancer immunotherapy. Cancer Res. 1973 Sep;33(9):1987–1997. [PubMed] [Google Scholar]
  12. Mohr S. J., Chirigos M. A., Fuhrman F., Smith G. Enhancement of a tumor allograft in BALB/c x DBA/2 F1 mice by pyran copolymer. Cancer Res. 1976 Apr;36(4):1315–1319. [PubMed] [Google Scholar]
  13. Nigam V. N., Brailovsky C. A., Chopra C. Maltose tetrapalmitate, a nontoxic immunopotentiator with antitumor activity. Cancer Res. 1978 Oct;38(10):3315–3321. [PubMed] [Google Scholar]
  14. Proctor J. W., Auclair B. G., Stokowski L., Mansell W. A., Shibata H. Comparison of effect of BCG, glucan and levamisole on B16 melanoma metastases. Eur J Cancer. 1977 Feb;13(2):115–122. doi: 10.1016/0014-2964(77)90189-x. [DOI] [PubMed] [Google Scholar]
  15. Ribi E. E., Cantrell J. L., Von Eschen K. B., Schwartzman S. M. Enhancement of endotoxic shock by N-acetylmuramyl-L-alanyl-(L-seryl)-D-isoglutamine (muramyl dipeptide). Cancer Res. 1979 Nov;39(11):4756–4759. [PubMed] [Google Scholar]
  16. Weissman R. M., Coffey D. S., Scott W. W. Cell kinetic studies of prostatic cancer: adjuvant therapy in animal models. Oncology. 1977;34(3):133–137. doi: 10.1159/000225206. [DOI] [PubMed] [Google Scholar]
  17. Yarkoni E., Rapp H. J. Influence of oil concentration on the efficacy of tumor regression by emulsified components of mycobacteria. Cancer Res. 1979 Feb;39(2 Pt 1):535–537. [PubMed] [Google Scholar]
  18. Zbar B., Bernstein I. D., Rapp H. J. Suppression of tumor growth at the site of infection with living Bacillus Calmette-Guérin. J Natl Cancer Inst. 1971 Apr;46(4):831–839. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES